• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

This product is currently not available for purchase.

RELATED PRODUCTS

Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy. Product Image

Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.

  • ID: 1667972
  • December 2010
  • 416 pages
  • Datamonitor

Introduction

Datamonitor forecasts the non-insulins antidiabetics market to grow to $18.8 billion in 2019 for the seven major markets, with pipeline products contributing 39% of sales. GLP-1 agonists are driving pipeline growth, and the first launch of the novel SGLT-2 inhibitor class is also forecast.

Scope

-Comprehensive analysis of the current non-insulin antidiabetic pipeline detailing the broad range of developmental classes.

-A detailed clinical and commercial assessment of all key emerging therapies.

-Sales based sales forecasts for key late-stage developmental non-insulin antidiabetics agents in the seven major markets to 2019.

-Analysis of unmet needs in non-insulin diabetes therapies and key development R&D strategies in light of regulatory changes.

Highlights

A huge number of molecules are in development as non-insulin antidiabetics to meet the increase in patient population and disease unmet needs. 179 candidates are in clinical trials, and 16 Big Pharma companies are engaged in diabetes drug development.

GLP-1 agonists are likely to be the most successful pipeline candidates, and the class pipeline is forecast READ MORE >

Note: Product cover images may vary from those shown

Overview
Catalyst
Summary
About Datamonitor Healthcare
About the Cardiovascular and diabetes pharmaceutical analysis team
Executive Summary
Strategic scoping and focus
Datamonitor insight into the disease market
Related reports
Upcoming related reports

Table of Figures
Table of tables
1. Pipeline Overview and Dynamics
Key findings
Pipeline overview
Increase in development candidates as western world focuses on diabetes
Non-insulin antidiabetics: a diverse pipeline
Incretin mimetic classes dominate pipeline
Forecast pipeline 2010-19
Comparative forecast
Market dominated by Big Pharma and single candidate companies
Key companies involved in the non-insulins pipeline
AstraZeneca
Roche
Eli Lilly
GlaxoSmithKline
Takeda
2. Epidemiology of Diabetes
Key findings
Introduction
Disease definition, classification and diagnosis criteria
Strengths and weaknesses of Datamonitor's epidemiologic projections
Risk factors of type 1 diabetes
Genetics
Environment
Ethnicity
Gender
Age
Global variation and temporal trends of incidence and prevalence of diabetes mellitus
Global variation of incidence and prevalence of type 1 diabetes
Global variation of type 2 diabetes prevalence
Temporal trends of type 1 diabetes mellitus
Temporal trends of type 2 diabetes mellitus
Prevalence
Incidence
Epidemiologic forecasting of type 1 diabetes mellitus
Sources of epidemiologic data
Description of methods
US
Japan
France
Germany
Italy
Spain
UK
Results for type 1 diabetes
Incidence
Prevalence
Risk factors of type 2 diabetes
Age
Genetic history
Race
Gender
Diet and exercise
Co-morbidities of type 2 diabetes
Overweight and obesity
Smoking
Hypertension and high cholesterol
Epidemiologic forecasting of type 2 diabetes mellitus
Sources of epidemiologic data
Description of methods
US
Japan
France
Germany
Italy
Spain
UK
Diagnosis rates
Results for type 2 diabetes prevalence
Current diagnosed prevalent cases and future trends
Diagnosis rates of type 2 diabetes in 2010
Prevalence of impaired glucose tolerance
Discussion
Conclusions
3. Disease Overview - Market Potential
Key findings
Definition
Current treatment options
Type 1 diabetes
Type 2 diabetes
Current gold standard and comparator therapies
Metformin - first-line treatment
Januvia - the gold-standard second-line oral antidiabetic
Byetta - injectable non-insulin therapy
Current market overview
Unmet needs in non-insulin antidiabetic therapies
Unmet market needs
Unmet market need 1: routine screening for the detection of type 2 diabetes mellitus
Unmet market need 2: greater patient awareness and education
Unmet market need 3: better treatment guidelines and physician education
Unmet clinical needs
Unmet clinical need 1: improved efficacy-safety balance for non-insulin antidiabetics
Unmet clinical need 2: improving cardiovascular mortality
Unmet clinical need 3: durability of therapy
Unmet clinical need 4: stability of glucose control and avoiding hypoglycemia
Unmet clinical need 5: better tolerability of non-insulin antidiabetics
Target product profile versus current level of attainment
4. R&D Approach
Key findings
Clinical trial design in non-insulin antidiabetics
Efficacy
Control of average blood glucose levels
Insulin
Blood markers
Weight loss
Safety and side effects
Weight gain
Cardiovascular endpoints
The Bydureon tQT requirement: what does it mean?
Comparators: add-on versus replacement therapy
Future trends
Safety
Positive macrovascular effects
Combinations
5. Pipeline Analysis & Forecasts: GLP-1 Agonists
Key findings
Overview for GLP-1 agonists
Biological effects of GLP-1
Marketed GLP-1 agonists
Byetta (exenatide, Amylin/Eli Lilly)
Victoza (liraglutide, Novo Nordisk)
Class attributes and concerns
General long-term safety concerns
Pancreatitis
Thyroid cancer and C-cell hyperplasia
Gastrointestinal side effects
Antibody formation and immunogenic reactions
Pipeline summary and comparative forecasts
Pipeline summary
Pipeline prospects
Comparative forecasts
Bydureon (exenatide long-acting release, Amylin/Eli Lilly)
Drug profile
Clinical trial data
Trial results
Ongoing trials for Bydureon
SWOT analysis
Datamonitor drug assessment summary for Bydureon
Clinical and commercial attractiveness
Commercial attractiveness
Clinical attractiveness
Bydureon's delivery mode attractiveness: needle size and premixing
Satisfaction of unmet needs
Forecasts to 2019
Lixisenatide (AVE-0010, Sanofi-Aventis/Zealand Pharma)
Drug profile
Clinical trial data
SWOT analysis
Datamonitor drug assessment summary for lixisenatide
Clinical and commercial attractiveness
Commercial attractiveness
Clinical attractiveness
Satisfaction of unmet needs
Forecasts to 2019
Syncria (albiglutide/GlaxoSmithKline)
Drug profile
Clinical trial data
SWOT analysis
Datamonitor drug assessment summary for Syncria
Clinical and commercial attractiveness
Satisfaction of unmet needs
Forecasts to 2019
LY2189265 (Eli Lilly)
Drug profile
Clinical trial data
SWOT analysis
Datamonitor drug assessment summary for LY2189265
Clinical and commercial attractiveness
Satisfaction of unmet needs
Forecasts to 2019
Taspoglutide (Roche/Ipsen/Teijin/Chugai)
Drug profile
Clinical trial data
Trial results
Ongoing trials
SWOT analysis
Datamonitor drug assessment summary for taspoglutide
Clinical and commercial attractiveness
Satisfaction of unmet needs
Forecasts to 2019
Other GLP-1 agonist drugs
Exenatide formulations
ITCA 650 (Intarcia Therapeutics)
Exenatide once-monthly (Amylin/Eli Lilly)
Exenatide transdermal (Amylin/Eli Lilly/Altea)
Exenatide intranasal (Amylin/Marina Biotech)
PT-302 (Peptron/NeoPharma)
ORMD 0901 (Oramed)
Other GLP-1 agonists
CJC-1134-PC (ConjuChem)
NN-9535 (semaglutide; Novo Nordisk), NN-9924, NN-9925
CMC3.1-AC100 (CellMed/AstraZeneca)
MKC253 (Mannkind)
TTP-054 (TransTech)
Uni-rE-4 (Uni-Bio Sciences)
MAR701 (Marcadia Biotech)
CVX-096 (Pfizer)
HM11260C (Hanmi)
6. Pipeline Analysis & Forecasts: DPP-4 inhibitors
Key findings
Overview for dipeptidyl peptidase-IV (DPP-4) inhibitors
Biological effects of DPP-4 inhibitors
Currently marketed DPP-4 inhibitors
Januvia franchise
Januvia franchise pipeline
Onglyza franchise
Onglyza franchise pipeline
Galvus franchise
Pipeline summary and comparative forecasts
Pipeline summary
Comparative forecasts
Nesina (alogliptin; Takeda)
Drug overview
Drug profile
Clinical trial data
SWOT analysis
Datamonitor drug assessment summary for Nesina
Clinical and commercial attractiveness
Commercial attractiveness
Clinical potential
Satisfaction of unmet needs
Forecasts to 2019
Linagliptin (Boehringer Ingelheim)
Drug overview
Drug profile
Clinical trial data
Trial results
Ongoing trials
SWOT analysis
Datamonitor drug assessment summary for linagliptin
Clinical and commercial attractiveness
Commercial considerations
Patient potential
Satisfaction of unmet needs
Forecasts to 2019
Other DPP-4 inhibitors
PHX1149T (dutogliptin; Phenomix)
MP-513 (teneligliptin/Mitsubishi Tanabe Pharma)
LC15-0444 (LG Life Sciences Korea)
SK-0403 (Kowa/Sanwa Kagaku Kenkyusho)
Early Phase DPP-4 inhibitors
TAK-472 (Takeda)
AMG-222 (Amgen/Servier)
KRP-104 (Kyorin)
ARI-2243 (Arisaph)
DSP-7238 (Dainippon Sumitomo)
DA-1229 (Dong-A)
GRC-8200 (Glenmark)
7. Pipeline Analysis & Forecasts: SGLT-2 Inhibitors
Key findings
Overview for SGLT-2 Inhibitors
Biological effects of SGLT-2 inhibitors
Clinical use and place in the treatment algorithm
Clinical and commercial significance of genital and urinary tract infections
General safety concerns
Pipeline summary and comparative forecasts
Pipeline summary
Comparative forecasts
Dapagliflozin (dapagliflozin/Bristol-Myers Squibb and AstraZeneca)
Drug overview
Drug profile
Clinical trial data
Trial results
Ongoing clinical trials
SWOT analysis
Datamonitor drug assessment summary for dapagliflozin
Clinical and commercial attractiveness
Patient potential
Satisfaction of unmet needs
Forecasts to 2019
Canagliflozin (Mitsubishi Tanabe Pharma and Johnson & Johnson)
Drug overview
Drug profile
Clinical trial data
Trial results
Ongoing clinical trials
SWOT analysis
Datamonitor drug assessment summary for canagliflozin
Clinical and commercial attractiveness
Satisfaction of unmet needs
Forecasts to 2019
ASP1941 (Astellas Pharma/Kotobuki Pharmaceutical Co. Ltd)
Drug overview
Drug profile
Clinical trial data
Trial results
Ongoing clinical trials
SWOT analysis
Datamonitor drug assessment summary for ASP1941
Clinical and commercial attractiveness
Satisfaction of unmet needs
Forecasts to 2019
BI 10773 (Boehringer Ingelheim)
Drug overview
Drug profile
Clinical trial data
Trial results
Ongoing clinical trials
SWOT analysis
Datamonitor drug assessment summary for BI 10773
Clinical and commercial attractiveness
Satisfaction of unmet needs
Forecasts to 2019
Other SGLT-2 inhibitors in development
RG7201 (Roche, Chugai)
LX4211 (Lexicon)
TS-071 (Taisho)
ISIS-SGLT2Rx (Isis)
DSP-3235 (GlaxoSmithKline/Dainippon Sumitomo)
SGLT-2 inhibitor drugs recently discontinued
Remogliflozin (GlaxoSmithKline/Kissei)
Sergliflozin (GlaxoSmithKline/Kissei)
AVE-2268
YM543 (Astellas/Kotobuki)
8. Pipeline Analysis & Forecasts: Autoimmune Therapies
Key findings
Overview for autoimmune therapies
The need for beta-cell preservation and autoimmune treatment
Pipeline summary and comparative forecasts
Pipeline summary
Comparative forecasts
Diamyd (rhGAD65, Diamyd Therapeutics AB/Johnson & Johnson)
Drug profile
Clinical trial data
Trial results
Ongoing trials
SWOT analysis
Datamonitor drug assessment summary for Diamyd
Clinical and commercial attractiveness
Satisfaction of unmet needs
Forecasts to 2019
Otelixizumab (GlaxoSmithKline)
Drug profile
Clinical trial data
SWOT analysis
Datamonitor drug assessment summary for otelixizumab
Clinical and commercial attractiveness
Satisfaction of unmet needs
Forecasts to 2019
Other autoimmune therapies in development
Teplizumab (Eli Lilly/MacroGenics)
DiaPep277 (Andromeda Biosciences/Teva)
NI-0401 (NovImmune)
BGP-15 (N-Gene)
Thymoglobulin (Genzyme)
BHT-3021 (Bayhill/Roche)
IL-7 stimulated immunoregulatory dendritic cells (University of Pittsburgh)
IBC-VS01 (Joslin Diabetes Center)
9. Other Non-insulin Antidiabetics
Key findings
PPAR modulators
Overview of PPAR modulators
Marketed PPAR-gammas
Actos (pioglitazone, Takeda)
Avandia (rosiglitazone, GlaxoSmithKline)
Pipeline PPAR-gamma modulators
Balaglitazone (Dr Reddy's/Rheoscience)
INT-131 (InteKrin)
THR-0921 (Theracos/Egret)
Mitoglitazone (Metabolic Solutions Development)
Pipeline pan-PPAR agonists
Lobeglitazone (Chong Kun Dang)
Indeglitazar (Plexxikon)
Chiglitazar (Shenzhen Chipscreen Biosciences)
Pipeline dual PPAR-alpha/PPAR-delta agonists
GFT505 (Genfit)
Pipeline dual PPAR-alpha/PPAR-gamma agonists
AVE-0897 (Genfit/Sanofi-Aventis)
DSP-8658 (Dainippon Sumitomo)
ZYH-2 (Zydus-Cadila)
Pipeline dual PPAR-delta/PPAR-gamma agonist
DB-959 (DARA)
Pipeline PPAR-alpha agonists and combinations
CRx-401 (CombinatoRx)
KRP-101 (Kyorin)
Unknown mechanisms
PN-2034 (WellStat/Sanofi-Aventis)
VVP-808 (Verva)
Late-stage PPAR agonist development compounds recently discontinued in type 2 diabetes
Aleglitazar (R-1439/Hoffmann-La Roche)
MBX-102 (Metabolex/Johnson and Johnson)
Rivoglitazone (Daiichi-Sankyo)
Anti-inflammatory therapies
IL-1 beta antagonists
ACZ885 (canakinumab; Novartis)
XOMA-052 (Xoma)
LY2189102 (Eli Lilly)
BLX-1002 (Orchid/BEXEL)
CYT-013-IL1bQb (Cytos Biotechnology)
NF-kappa B pathway inhibitors
Triolex (HE3286, Harbor BioSciences)
VGX-1027 (VGX Pharmaceuticals)
Other anti-inflammatory therapies
BMS-741672 (Bristol-Myers Squibb)
CCX-140 (ChemoCentryx)
Lisofylline (DiaKine)
Salsalate
Autonomic and central nervous system therapies
Cycloset (VeroScience/Santarus)
Cannabinoid (CB) -1 antagonist
Inhibitors of glycogenolysis and gluconeogenesis
Glucokinase activators
LY2599506 (Eli Lilly)
ARRY-403 (Array/Amgen)
TTP-399 (TransTech Pharma/ Forest Labs)
AZD1656 (AstraZeneca)
MK-0599 (Banyu/Merck)
TAK-329 (Takeda)
Glucagon receptor antagonists
AMG-477 (Amgen)
ISIS GCGRRx (Isis)
PTP-1B inhibitors
ISIS 113715 (Isis)
TTP814 (TransTech)
Glycogen phosphorylase inhibitor
GSK1362885 (GlaxoSmithKline)
GPR119 agonists
MBX-2982 (Metabolex/Sanofi-Aventis)
APD-597 (Ortho-McNeil, Arena)
PSN821 (Astellas)
GSK1292263 (GlaxoSmithKline)
11-beta-HSD inhibitors
INCB-13739 (Incyte)
JTT-654 (Japan Tobacco/Akros Pharma)
RG-7234 (Roche) and RG-4929 (Roche)
HSD-016 (Pfizer)
BMS-816336 (Bristol-Myers Squibb)
AZD4017 and AZD8329 (AstraZeneca)
AMG-221 (Amgen)
DGAT-1 inhibitors
LCQ-908 (Novartis)
PF-04620110 (Pfizer/Bristol-Myers Squibb)
AZD7687 (AstraZeneca)
Appetite regulators
Unacylated ghrelin (Alizé/Eli Lilly)
RG7089 (Roche)
AP1030 (Action Pharma)
Fatty acid digestion and metabolism
Bile acid sequestrants
Welchol (Colesevelam, Daiichi Sankyo)
Colestilan (Mitsubishi Tanabe)
Other
JNJ-16269110 (Johnson & Johnson)
JTT-130 (Japan Tobacco)
Islet transplantation and neogenesis
DiabeCell (Living Cell Technologies)
Human islet allografts (ViaCyte)
Exsulin (Kinexum Metabolics)
Combinations
Metgluna (mitiglinide+metformin, Kissei/Elixir)
DM-71, DM-83 (DiaMedica)
Qnexa (Vivus)
Other modes of action
Ramipril (King Pharmaceuticals)
D-tagatose (Spherix)
DM-99 (DiaMedica)
Sirtuins
Resveratrol (GlaxoSmithKline)
SRT-2104 (GlaxoSmithKline)
GSK184072 (GlaxoSmithKline)
Eprodisate (BELLUS/Celtic Therapeutic)
AR-9281 (Arête Therapeutics)
Ranolazine (Gilead Sciences)
Bibliography
References for Chapter 1. Pipeline overview
Articles
Other Sources
References for Chapter 2. Epidemiology of diabetes
Type 1 diabetes epidemiology references
Type 2 diabetes epidemiology references
References for Chapter 3. Disease overview
Articles
Other Sources
Datamonitor reports
References for Chapter 4. R&D approach
Articles
Other sources
References for Chapter 5. Pipeline analysis & forecasts: GLP-1 agonists
Articles
Other sources
References for Chapter 6. Pipeline analysis & forecasts: DPP-4 inhibitors
Articles
Other sources
References for Chapter 7. Pipeline analysis & forecasts: SGLT-2 inhibitors
Articles
Other Sources
References for Chapter 9. Pipeline analysis & forecasts: Autoimmune therapies
Articles
Other sources
References for Chapter 10. Other non-insulin antidiabetics
Articles
Other Sources
Appendix A - Market Assumptions
New product launches
Patent expiries
Methodology and data definitions, limitations and assumptions
Standard units
Datamonitor forecast methodology
Japan methodology
Exchange rates
Datamonitor drug assessment scorecard
Appendix B
Contributing experts
Conferences attended
Report methodology
About Datamonitor
About Datamonitor Healthcare
About the Cardiovascular and Diabetes analysis team
Datamonitor consulting
Disclaimer
List of Tables
Table 1: Non-insulin pipeline products in clinical development for diabetes, 2010
Table 2: Non-insulin antidiabetic pipeline by broad mechanism of action, 2010
Table 3: Non-insulin antidiabetic pipeline by narrow mechanism of action, 2010
Table 4: Forecast non-insulin antidiabetics pipeline drugs in the seven major markets, 2010-19
Table 5: Sales forecast for pipeline products in non-insulin antidiabetics in the seven major markets ($m), 2010-19
Table 6: Big Pharma non-insulin antidiabetic pipeline, 2010
Table 7: 1999 World Health Organization definitions of diabetes mellitus and prediabetes
Table 8: Summary of sources used to forecast incidence of type 1 diabetes mellitus in those aged 0-14 years, published between 1993 and 2008
Table 9: Incident cases of type 1 diabetes mellitus in those aged 0-14 in the seven major markets, 2010-2020
Table 10: Incidence rates per 100,000 of type 1 diabetes mellitus in those aged 0-14 in the seven major markets, 2010-2020
Table 11: Number of prevalent cases and percent of population that has type 1 diabetes in those aged 0-79 in the seven major markets, 2010
Table 12: Summary of sources used in analyses of type 2 diabetes mellitus, published between 1999 and 2009
Table 13: Diagnosed prevalent cases (000s) of type 2 diabetes mellitus in those aged 20-79 years, in the seven major markets, 2010-2020
Table 14: Percent of population aged 20-79 years with type 2 diabetes mellitus in the seven major markets (%), 2010-2020
Table 15: Prevalent cases of type 2 diabetes in the seven major markets by age group, 2010
Table 16: Percentage of type 2 diabetes cases in each age group by country in the seven major markets (%), 2010
Table 17: Percentage of undiagnosed diabetes in those aged 20-79 in the seven major markets , 2010 (%)
Table 18: Prevalence of impaired glucose tolerance in those aged 20-79 years (000s) in the seven major markets, 2010-2020
Table 19: Prevalence rates of impaired glucose tolerance in those aged 20-79 years in the seven major markets (%), 2010-2020
Table 20: EASD/ADA Summary of glucose-lowering interventions, 2009
Table 21: Comparator non-insulin treatments for type 2 diabetes, 2009
Table 22: Metformin - drug profile, 2010
Table 23: Januvia - drug profile, 2010
Table 24: Byetta - drug profile, 2010
Table 25: Leading non-insulin antidiabetic brands in the seven major markets, 2009
Table 26: Ability of current class comparators to meet unmet needs in diabetes, 2010
Table 27: Byetta - drug profile, 2010
Table 28: Victoza franchise (Novo Nordisk) - drug profile, 2010
Table 29: Key products in late-stage R&D glucagon-like peptide-1 (GLP-1) agonists pipeline for diabetes, 2010
Table 30: Forecast assumptions for glucagon-like peptide-1 (GLP-1) agonist class pipeline antidiabetics across the seven major markets, 2009
Table 31: Sales forecasts for pipeline glucagon-like peptide-1 (GLP-1) agonists in the seven major markets ($m), 2009-2019
Table 32: Bydureon franchise (Amylin/Eli Lilly) - drug profile, 2010
Table 33: Bydureon (exenatide long-acting, Amylin/Eli Lilly): DURATION trials results summary, 2010
Table 34: DURATION-2 clinical trial data for Bydureon (exenatide long-acting, Amylin/Eli Lilly) with comparator prescription data
Table 35: DURATION-4 Bydureon (exenatide long-acting, Amylin/Eli Lilly) trial top line results
Table 36: Bydureon (exenatide long-acting, Amylin/Eli Lilly): ongoing Phase III trials in type 2 diabetes, 2010
Table 37: Ability of Bydureon (exenatide long-acting, Amylin/Eli Lilly) vs GLP-1 agonist class comparator Byetta (exenatide, Amylin/Eli Lilly) to address unmet needs in type 2 diabetes
Table 38: Sales forecasts ($m) for Bydureon (exenatide long-acting, Amylin/Eli Lilly) in the seven major markets, 2010-19
Table 39: Factors affecting revenues of Bydureon (exenatide long-acting, Amylin/Eli Lilly), 2010-19
Table 40: Lixisenatide franchise (Sanofi-Aventis/ Zealand Pharma) - drug profile, 2010
Table 41: Lixisenatide (Sanofi-Aventis/Zealand Pharma): ongoing Phase III trials in type 2 diabetes, 2010
Table 42: Ability of lixisenatide (Sanofi-Aventis/Zealand Pharma) vs GLP-1 agonist class comparator Byetta (exenatide, Amylin/Eli Lilly) to address unmet needs in type 2 diabetes
Table 43: Sales forecasts ($m) for lixisenatide (Sanofi-Aventis/Zealand Pharma) in the seven major markets, 2010-19
Table 44: Factors affecting revenues of lixisenatide (Sanofi-Aventis/Zealand Pharma), 2010-19
Table 45: Syncria (albiglutide, GlaxoSmithKline) - drug profile, 2010
Table 46: Ongoing Phase III trials of Syncria (albiglutide, GlaxoSmithKline), 2010
Table 47: Ability of Syncria (albiglutide, GlaxoSmithKline) vs GLP-1 agonist class comparator Byetta (exenatide, Amylin/Eli Lilly) to address unmet needs in type 2 diabetes
Table 48: Sales forecasts ($m) for Syncria (albiglutide, GlaxoSmithKline) in the seven major markets, 2010-19
Table 49: Factors affecting revenues of Syncria (albiglutide, GlaxoSmithKline), 2010-19
Table 50: LY2189265 (Eli Lilly) - drug profile, 2010
Table 51: LY2189265 (Eli Lilly): ongoing Phase III trials, 2010
Table 52: Ability of LY2189265 (Eli Lilly) vs GLP-1 agonist class comparator Byetta (exenatide, Amylin/Eli Lilly) to address unmet needs in type 2 diabetes
Table 53: Sales forecasts ($m) for LY2189265 (Eli Lilly) in the seven major markets, 2010-19
Table 54: Factors affecting revenues of LY2189265 (Eli Lilly), 2010-19
Table 55: Taspoglutide (Roche/Ipsen) - drug profile, 2010
Table 56: Taspoglutide (Roche/Ipsen/Teijin/Chugai): ongoing- Phase III trials in type 2 diabetes, 2010
Table 57: Ability of Taspoglutide (Roche/Ipsen/Teijin/Chugai) vs GLP-1 agonist class comparator Byetta (exenatide, Amylin/Eli Lilly) to address unmet needs in type 2 diabetes
Table 58: Sales forecasts ($m) for taspoglutide (Roche/Ipsen/Teijin/Chugai) in the seven major markets, 2010-19
Table 59: Factors affecting revenues of taspoglutide (Roche/Ipsen/Teijin/Chugai), 2010-19
Table 60: Januvia - drug profile, 2010
Table 61: Janumet - drug profile, 2010
Table 62: Sales forecasts ($m) for Januvia + pioglitazone (Merck & Co) in the seven major markets, 2010-19
Table 63: Sales forecasts ($m) for Januvia + simvastatin (Merck & Co) in the seven major markets, 2010-19
Table 64: Onglyza - drug profile, 2010
Table 65: Sales forecasts ($m) for Onglyza + metformin XR (Bristol-Myers Squibb/AstraZeneca) in the seven major markets, 2010-19
Table 66: Key products in late-stage R&D dipeptidyl peptidase-IV (DPP-4) pipeline for diabetes, 2010
Table 67: Forecast assumptions for dipeptidyl peptidase-IV (DPP-4)inhibitor class pipeline antidiabetics across the seven major markets, 2010
Table 68: Sales forecasts for pipeline dipeptidyl peptidase-IV (DPP-4) inhibitors in the seven major markets ($m), 2010-19
Table 69: Nesina (alogliptin, Takeda) - drug profile, 2010
Table 70: Ability of Nesina vs DPP-4 inhibitor class comparator Januvia (sitagliptin, Merck & Co) to address unmet needs in type 2 diabetes
Table 71: Sales forecasts ($m) for Nesina franchise (Takeda) by region in the seven major markets, 2010-19
Table 72: Factors affecting revenues of Nesina franchise (Takeda), 2010-19
Table 73: Linagliptin (Boehringer Ingelheim) - drug profile, 2010
Table 74: Linagliptin (Boehringer Ingelheim): summary of Phase III efficacy trial results, 2010
Table 75: Linagliptin (Boehringer Ingelheim): ongoing Phase III trials in type 2 diabetes, 2010
Table 76: Ability of linagliptin vs DPP-4 inhibitor class comparator Januvia (sitagliptin, Merck & Co) to address unmet needs in type 2 diabetes
Table 77: Sales forecasts ($m) for linagliptin (Boehringer Ingelheim) by region in the seven major markets, 2010-19
Table 78: Factors affecting revenues of linagliptin (Boehringer Ingelheim), 2010-19
Table 79: Key products in late-stage sodium-dependent glucose co-transporter 2 (SGLT-2) R&D pipeline for diabetes, 2010
Table 80: Forecast assumptions for sodium-dependent glucose co-transporter 2 (SGLT-2) inhibitor class pipeline antidiabetics across the seven major markets, 2010
Table 81: Sales forecasts for pipeline sodium-dependent glucose co-transporter 2 (SGLT-2) inhibitors in the seven major markets ($m), 2010-19
Table 82: Dapagliflozin (Bristol-Myers Squibb/AstraZeneca) - drug profile, 2010
Table 83: Dapagliflozin+metformin (Bristol-Myers Squibb/AstraZeneca) - drug profile, 2010
Table 84: Dapagliflozin (Bristol-Myers Squibb/AstraZeneca): Phase III efficacy trial results, 2010
Table 85: Dapagliflozin (Bristol-Myers Squibb/AstraZeneca): ongoing Phase III trials, 2010
Table 86: Ability of dapagliflozin (Bristol-Myers Squibb/AstraZeneca) vs oral antidiabetic gold standard Januvia (sitagliptin, Merck & Co) to address unmet needs in type 2 diabetes
Table 87: Sales forecasts ($m) for dapagliflozin franchise (Bristol-Myers Squibb/AstraZeneca) by region in the seven major markets, 2010-19
Table 88: Factors affecting revenues of dapagliflozin franchise (Bristol-Myers Squibb/AstraZeneca), 2010-19
Table 89: Canagliflozin (Johnson & Johnson /Mitsubishi Tanabe) - drug profile, 2010
Table 90: Canagliflozin (Johnson & Johnson /Mitsubishi Tanabe): ongoing Phase III clinical trials, 2010
Table 91: Ability of canagliflozin (Johnson & Johnson /Mitsubishi Tanabe) vs oral antidiabetic gold standard Januvia (sitagliptin, Merck & Co) to address unmet needs in type 2 diabetes
Table 92: Sales forecasts ($m) for canagliflozin (Johnson & Johnson /Mitsubishi Tanabe) by region in the seven major markets, 2010-19
Table 93: Factors affecting revenues of canagliflozin franchise (Johnson & Johnson /Mitsubishi Tanabe), 2010-19
Table 94: ASP1941 (Astellas Pharma/Kotobuki Pharmaceutical) - drug profile, 2010
Table 95: ASP1941 (Astellas Pharma/Kotobuki Pharmaceutical) - ongoing Phase III trials, 2010
Table 96: Ability of ASP1941 (Astellas Pharma/Kotobuki Pharmaceutical) vs oral antidiabetic gold standard Januvia (sitagliptin, Merck & Co) to address unmet needs in type 2 diabetes
Table 97: Sales forecasts ($m) for ASP1941 (Astellas Pharma/Kotobuki Pharmaceutical) by region in the seven major markets, 2010-19
Table 98: Factors affecting revenues of ASP1941 (Astellas Pharma/Kotobuki Pharmaceutical), 2010-19
Table 99: BI 10773 (Boehringer Ingelheim) - drug profile, 2010
Table 100: BI 10773 (Boehringer Ingelheim) - ongoing Phase III trials, 2010
Table 101: Ability of BI 10773 (Boehringer Ingelheim), vs oral antidiabetic gold standard Januvia (sitagliptin, Merck & Co) to address unmet needs in type 2 diabetes
Table 102: Sales forecasts ($m) for BI 10773 (Boehringer Ingelheim) by region in the seven major markets, 2010-19
Table 103: Factors affecting revenues of BI 10773 (Boehringer Ingelheim), 2010-19
Table 104: Key products in late-stage R&D autoimmune therapies pipeline for diabetes, 2010
Table 105: Forecast assumptions for autoimmune therapy class pipeline antidiabetics across the seven major markets, 2010
Table 106: Sales forecasts for pipeline autoimmune therapies in the seven major markets ($m), 2010-19
Table 107: Diamyd (Diamyd/Johnson & Johnson) - drug profile, 2010
Table 108: Diamyd (rhGAD65, Diamyd/Johnson&Johnson): ongoing Phase III clinical trials, 2010
Table 109: Ability of Diamyd (rhGAD65, Diamyd/Johnson&Johnson) vs insulins to address unmet needs in type 1 diabetes
Table 110: Sales forecasts ($m) for Diamyd (rhGAD65, Diamyd/Johnson & Johnson) by region in the seven major markets, 2010-19
Table 111: Factors affecting revenues of Diamyd (rhGAD65, Diamyd/Johnson&Johnson), 2010-19
Table 112: Otelixizumab (GlaxoSmithKline/Tolerx) - drug profile, 2010
Table 113: Otelixizumab (Tolerx/GlaxoSmithKline): ongoing Phase III trials, 2010
Table 114: Ability of otelixizumab (Tolerx/GlaxoSmithKline) vs insulins to address unmet needs in type 1 diabetes
Table 115: Sales forecasts ($m) for otelixizumab (Tolerx/GlaxoSmithKline) by region in the seven major markets, 2010-19
Table 116: Factors affecting revenues of otelixizumab (Tolerx/GlaxoSmithKline), 2010-19
Table 117: Actos - drug profile, 2010
Table 118: Actos + Blopress (pioglitazone + candesartan) sales ($m) in the seven major markets, 2010-19
Table 119: Datamonitor's estimated launch dates for diabetes products in the seven major markets, 2010-19
Table 120: Patent expiry or loss of market exclusivity dates for approved diabetes drugs in the seven major markets, 2010-19
Table 121: Datamonitor drug assessment parameters
List of Figures
Figure 75: Methodology for forecasting price to remove impact of currency fluctuations on future trends

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

Our Clients

Our clients' logos